References
- Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030–2036.
- Bush SP, Ruha A-M, Seifert SA, et al. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol. 2015;53(1):37–45.
- Gerardo CJ, Vissoci JRN, Brown MWJ, et al. Coagulation parameters in copperhead compared to other crotalinae envenomation: secondary analysis of the F(ab’)2 versus Fab antivenom trial. Clin Toxicol. 2017;55(2):109–114.
- Ruha A-M, Kleinschmidt KC, Greene S, et al. The epidemiology, clinical course, and management of snakebites in the North american snakebite registry. J Med Toxicol. 2017;13(4):309–320.
- Lavonas EJ, Gerardo CJ, O'Malley G, et al. Initial experience with crotalidae polyvalent immune fab (ovine) antivenom in the treatment of copperhead snakebite. Ann Emerg Med. 2004;43(2):200–206.
- Gerardo CJ, Quackenbush E, Lewis B, et al. The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: a randomized, double-blind, placebo-controlled, clinical trial. Ann Emerg Med. 2017;70(2):233–244.e3.
- Dart RC, Hurlbut KM, Garcia R, et al. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med. 1996;27(3):321–326.
- ANAVIP® crotalidae immune F(ab’)2 (equine) [package insert]. Franklin, TN: Rare Disease Therapeutics, Inc.; 2021.